Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay

Breast Cancer Research and Treatment

Volumn 41, Issue 2, 1996, Pages 161-170

  Kurbacher, Christian M ^a,f   Cree, Ian A ^b,e   Brenne, Ursula ^a   Bruckner, Howard W ^c   Kurbacher, Jutta A ^a   Mallmann, Peter ^a   Andreotti, Peter E ^d   Krebs, Dieter ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Atl Scientific Development Inc   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ATP bioluminescence; Breast cancer; Chemosensitivity assay; Doxorubicin; Mitoxantrone; Multidrug resistance

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOXORUBICIN; MITOXANTRONE;

ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 0029842406     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01807161     Document Type: Article

References (43)

1. Fisher B, Carbone P, Economou SG: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292: 117-122, 1975
2. Bonadonna G, Brusamolino E, Valagussa P: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405-410, 1976
3. Bonadonna G, Valagussa P: The contribution of medicine to the primary treatment of breast cancer. Cancer Res 48: 2314-2324, 1988
4. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127-2137, 1992
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901-906, 1995
6. Jones RB, Holland JF, Bhardwaj S et al.: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 5: 172-177, 1987
7. Ahman DL, Schaid D, Bisel HF: The effect on survival of initiating chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol 5: 1928-1932, 1987
8. Kardinal CG: Chemotherapy of breast cancer. In: Perry MC (ed.) The Chemotherapy Source Book. Williams & Wilkins, Baltimore, 1992, pp 949-988
9. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland CM, Robert NJ, Ager PJ, Levy L, Wolter J, Wozniak T, Fisher ER, Deutsch M: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483-1496, 1990
10. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood W, Barcos M, Henderson C: C-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994
11. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542-547, 1995
12. Dukart G, Iatropoulos MJ, Yacobi A: Comment on mitoxantrone. Drug Intell Clin Pharmacy 19: 216-218, 1985
13. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571, 1989
14. Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, Neeser E, von Ingersleben G, Hossfeld D, Caffier H, Souchon R, Waldmann R, Blümner E, Clark J: Prognostic subgroups: The key factor for treatment outcome in metastatic breast cancer. Results of a three-arm randomized multicenter trial comparing doxorubicin, epirubicin and mitoxantrone each in combination with cyclophosphamide. Onkologie 16: 344-353, 1993
15. Smith IE: Mitoxantrone (novantrone): A review of experimental and early clinical studies. Cancer Treat Rev 10: 103-115, 1983
16. Neidhart JA, Gochnour D, Roach R, Hoth D, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672-677, 1986
17. Andersson M, Mouridsen HT: Mitoxantrone as single agent chemotherapeutic agent for advanced breast cancer: The phase II trial experience. In: Mouridsen HT, Arlin ZA (eds) The Role of Mitoxantrone in Malignant Diseases. PharmaLibri Publ, Chicago, 1987, pp 31-47
18. Ahmann F, Garewal H, Schifman R, Celniker A, Rodney S: Intracellular adenosine triphosphate as a measure of human cell viability and drug modulated growth. In vitro Cell Develop Biol 23: 474-480, 1987
19. Andreotti PE, Linder D, Hartmann DM, Becker K, Herbst K, Cree IA, Bruckner HW: ATP tumor chemosensitivity assay application for solid tumors and leukemias. In: Szalay A, Kricka LJ, Stanley PE (eds) Chemiluminescence and Bioluminescence. Status Report. John Wiley & Sons: Chichester, 1993, pp 271-275
20. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Wood RAB, Linder D, Andreotti PE: Heterogeneity of chemosensitivity in human breast carcinoma: Use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 19: 242-249, 1993
21. Petty RD, Sutherland LA, Hunter EM, Cree IA: Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 10: 29-34, 1995
22. Sevin BU, Peng Z, Perras J, Ganjei P, Penalver G, Averette H: Application of an ATP bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31: 191-204, 1988
23. Andreotti PE, Thornwaite JT, Morse IS: ATP tumor chemosensitivity assay. In: Stanley PE, Kricka LJ (eds) Bioluminescence and Chemiluminescence: Current Status. John Wilcy & Sons, Chichester, 1991, pp 417-420
24. Cree IA, Pazzagli M, Mini E, Mazzei T, Hunter EMM, Sutherland LA, Pinzani P, Gerli A, Andreotti PE: Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anti-Cancer Drugs 6: 398-404, 1995
25. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW: TCA-100 Tumor Chemosensitivity Assay: Differences in sensitivity between cultured tumour cell lines and clinical studies. J Biolumin Chemilumin 9: 373-378, 1994
26. Kurbacher CM, Bruckner HW, Andreotti PE, Kurbacher JA, Sa G, Krebs D: In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtitre plate ATP bioluminescence assay. Anti-Cancer Drugs 6: 697-704, 1995
27. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Bruckner HW: Sensitivity testing of human tumors using a microplate ATP assay. In: Campbell AK, Kricka LJ, Stanley PE (eds) Bioluminescence and Chemiluminescence. Fundamentals and Applied Aspects. John Wiley & Sons, Chichester, 1994, pp 403-406
28. Kurbacher CM, Mallmann P, Kurbacher JA, Saß G, Andreotti PE, Rahmun A, Hübner H, Krebs D: In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer. Anticancer Res 14: 1961-1966, 1994
29. Koechli OR, Avner BP, Sevin BU, Avner B, Perras JP, Robinson DS, Averette HE: Application of the ATP-Cell Viability Assay in human breast cancer chemosensitivity testing. A report on the first results. J Surg Oncol 54: 119-125, 1993
30. Cree IA, Sutherland LA, Hunter EMM, Subedi AMC, James EA, Dewar JA, Preece PE, Andreotti PE: Validation of the TCA-100 tumour chemosensitivity assay (Abstract). J Tumor Marker Oncol 9: 42, 1994
31. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C, Bruckner HW: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276-5282, 1995
32. Bosanquet AG: Stability of solutions for antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and other anti-tumour antibiotics. Cancer Chemother Pharmacol 17: 1-10, 1986
33. Hunter EM, Sutherland LA, Cree IA, Subedi AM, Hartmann D, Linder D, Andreotti PE: The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anti-Cancer Drugs 5: 171-176, 1994
34. Alberts DS: Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Salmon SE (ed.) Cloning of Human Tumor Stem Cells. Alan R Liss Inc. New York, 1980, pp 351-359
35. Dalton WS, Alberts DS: Pharmacokinetics of mitoxantrone. In: Mouridsen HT, Arlin ZA (eds) The Role of Mitoxantrone in Malignant Diseases. PharmaLibri Publ, Chicago, 1987, pp 5-18
36. Silverman RA: Calculus with Analytical Geometry. Prentice Hall Inc., New Yersey, 1985, pp 416-418
37. Von Hoff DD, Clark GM, Weiss GR, Marshall MH, Buckok JB, Knight WA III, LeMaistre CF: Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4: 1827-1834, 1986
38. Maltere P, Martin M, Plot M, Manoux D, Maillart P, Combe M, Kamioner D, Serin D, Chalmin B, Renaud R, Grapin JP: Neoadjuvant chemotherapy with FNC (fluorouracil, mitoxantrone and cyclophosphamide) in operable locally advanced breast cancer (LABC) allows breast conservation (Abstract). Proc Amer Soc Clin Oncol 14: 92, 1995
39. Sandbach J, Von Hoff DD, Clark G, Cruz AB, O'Brien M: Direct cloning of human breast cancer in soft agar culture. Cancer 50: 1315-1321, 1982
40. Jones SE, Dean JC, Young LA, Salmon SE: The human tumor clonogenic assay in breast cancer, J Clin Oncol 3: 92-97, 1985
41. Koechli OR, Sevin BU, Perras J, Angioli R, Steren A, Rodriguez M, Averette HE: Growth characteristics of non-malignant cells in the ATP-Cell-Viability-Assay. Oncology 51: 35-41, 1994
42. Riggs CE: Antitumor antibiotics and related compounds. In: Perry MC (ed.) The Chemotherapy Source Book. Williams & Wilkins, Baltimore, 1992, pp 318-358
43. Fields K, Perkins J, Elfenbein G, Ballester O, Hiemenz J, Goldslein S, Zorsky P, Kronish L: A phase I dose escalation trial of high dose taxol®, novantrone®, and thiotepa (TNT) followed by autologous stem cell rescue (ASCR): Toxicity. (Abstract). Proc Amer Soc Clin Oncol 14: 322, 1995